Table 2 summary of the patients’ treatment, clinical and paraclinical characteristics during COVID-19.
Patient symptoms | |
Symptomatic | 78 (86%) |
Asymptomatic | 13 (14%) |
Presenting symptoms | |
Fever | 51 (56%) |
Cough | 37 (41%) |
SOB | 22 (24%) |
Runny nose | 18 (20%) |
Fatigue | 17 (19%) |
Throat pain | 12 (13%) |
Headache | 10 (11%) |
Diarrhea, vomiting, loss of smell, dizziness, myalgia abdominal pain and chest pain | <10% |
COVID-19 and associated infections therapy | |
Azithromycin | 05 (05%) |
Hydrochloroquine | 00 (00%) |
Azithromycin + Hydrochloroquine | 10 (11%) |
Antibiotics | 21 (23%) |
Steroids | 06 (07%) |
Others | 02 (02%) |
None | 47 (52%) |
Chest X-ray | 62 (68% of total patients) |
Normal | 26 (42%) |
Abnormal | 36 (58%) |
White blood cell count | 71(78% of total patients) |
Normal | 35 (49%) |
High | 09 (13%) |
Low | 27 (38%) |
Lymphocyte count | 69 (76% of total patients) |
Normal | 31 (45%) |
High | 02 (03%) |
Low | 36 (52%) |
Neutrophil count | 69 (76% of total patients) |
Normal | 39 (57%) |
High | 09 (13%) |
Low | 21 (30%) |
Platelet count | 71(78% of total patients) |
Normal | 37 (52%) |
High | 02 (03%) |
Low | 32 (45%) |
Ferritin level | 45 (49% of total patients) |
Normal | 12 (27%) |
High | 30 (67%) |
Low | 03 (06%) |
ESR level | 32 (35% of total patients) |
Normal | 08 (25%) |
High | 24 (75%) |
CRP level | 52 (57% of total patients) |
Normal | 07 (13%) |
High | 45 (87%) |
Albumin level | 57 (63%of total patients) |
Normal | 13 (23%) |
Low | 44 (77%) |
